On February 22, 2021 Zionexa reported that it has been working with SNMMI to seek proper Medicare reimbursement for Cerianna, radiolabeled 18F-fluoroestradiol indicated for use with positron emission tomography (PET) imaging for detection of estrogen receptor–positive lesions as an adjunct to biopsy in patients with recurrent or metastatic breast cancer (Press release, Zionexa, FEB 22, 2021, View Source [SID1234575386]). As of January 2021, the HOPPS published rate for this product is incorrect. Recently, the Centers of Medicare and Medicaid Services (CMS) confirmed their error in a HOPPS correction notice. The correct rate is $626.583 per millicurie instead of $0.752 per millicurie.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

CMS has told us that any corrections would be retroactive to January 1, 2021. SNMMI will notify their members and update the Q&As when any corrections are implemented. If you are encountering issues with your MAC, please notify SNMMI at [email protected].